Compare ATNI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATNI | ALLO |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.4M | 252.9M |
| IPO Year | 1991 | 2018 |
| Metric | ATNI | ALLO |
|---|---|---|
| Price | $20.98 | $1.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 55.8K | ★ 2.3M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $724,308,000.00 | N/A |
| Revenue This Year | $1.77 | N/A |
| Revenue Next Year | $2.06 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.76 | $0.86 |
| 52 Week High | $23.60 | $3.78 |
| Indicator | ATNI | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 64.97 | 57.36 |
| Support Level | $21.05 | $1.39 |
| Resistance Level | $21.99 | $1.52 |
| Average True Range (ATR) | 0.79 | 0.10 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 59.41 | 68.75 |
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.